BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 23591839)

  • 1. The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer.
    Dobbin ZC; Landen CN
    Int J Mol Sci; 2013 Apr; 14(4):8213-27. PubMed ID: 23591839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
    Mabuchi S; Kuroda H; Takahashi R; Sasano T
    Gynecol Oncol; 2015 Apr; 137(1):173-9. PubMed ID: 25677064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway.
    Elsayed AM; Bayraktar E; Amero P; Salama SA; Abdelaziz AH; Ismail RS; Zhang X; Ivan C; Sood AK; Lopez-Berestein G; Rodriguez-Aguayo C
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33668685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
    Ediriweera MK; Tennekoon KH; Samarakoon SR
    Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIM Kinases and Their Relevance to the PI3K/AKT/mTOR Pathway in the Regulation of Ovarian Cancer.
    Aziz AUR; Farid S; Qin K; Wang H; Liu B
    Biomolecules; 2018 Feb; 8(1):. PubMed ID: 29401696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CADM1 inhibits ovarian cancer cell proliferation and migration by potentially regulating the PI3K/Akt/mTOR pathway.
    Si X; Xu F; Xu F; Wei M; Ge Y; Chenge S
    Biomed Pharmacother; 2020 Mar; 123():109717. PubMed ID: 31865146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiRNAs and their interplay with PI3K/AKT/mTOR pathway in ovarian cancer cells: a potential role in platinum resistance.
    Gasparri ML; Besharat ZM; Farooqi AA; Khalid S; Taghavi K; Besharat RA; Sabato C; Papadia A; Panici PB; Mueller MD; Ferretti E
    J Cancer Res Clin Oncol; 2018 Dec; 144(12):2313-2318. PubMed ID: 30109500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HOTAIR/miR-326/FUT6 axis facilitates colorectal cancer progression through regulating fucosylation of CD44 via PI3K/AKT/mTOR pathway.
    Pan S; Liu Y; Liu Q; Xiao Y; Liu B; Ren X; Qi X; Zhou H; Zeng C; Jia L
    Biochim Biophys Acta Mol Cell Res; 2019 May; 1866(5):750-760. PubMed ID: 30742932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knockdown of Hypoxia-Inducible Factor 1α (HIF-1α) Promotes Autophagy and Inhibits Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway in Ovarian Cancer Cells.
    Huang J; Gao L; Li B; Liu C; Hong S; Min J; Hong L
    Med Sci Monit; 2019 Jun; 25():4250-4263. PubMed ID: 31175269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endoplasmic reticulum stress regulates proliferation, migration and invasion of human ovarian cancer SKOV3 cells through PI3K/AKT/mTOR signaling pathway.
    Yang N; Qu YJ; Cheng Y; Liang T; Zhang MN; Zhang D; Dong LN; Wang XW; Zhang GM
    Cancer Biomark; 2017 Jul; 19(3):263-269. PubMed ID: 28453460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long noncoding RNA-JPX predicts the poor prognosis of ovarian cancer patients and promotes tumor cell proliferation, invasion and migration by the PI3K/Akt/mTOR signaling pathway.
    Li J; Feng L; Tian C; Tang YL; Tang Y; Hu FQ
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8135-8144. PubMed ID: 30556851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer.
    Li H; Zeng J; Shen K
    Arch Gynecol Obstet; 2014 Dec; 290(6):1067-78. PubMed ID: 25086744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors.
    Smit DJ; Cayrefourcq L; Haider MT; Hinz N; Pantel K; Alix-Panabières C; Jücker M
    Cells; 2020 Sep; 9(9):. PubMed ID: 32962206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tanshinone I attenuates the malignant biological properties of ovarian cancer by inducing apoptosis and autophagy via the inactivation of PI3K/AKT/mTOR pathway.
    Zhou J; Jiang YY; Chen H; Wu YC; Zhang L
    Cell Prolif; 2020 Feb; 53(2):e12739. PubMed ID: 31820522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endoplasmic reticulum stress promotes autophagy and apoptosis and reverses chemoresistance in human ovarian cancer cells.
    Hu JL; Hu XL; Guo AY; Wang CJ; Wen YY; Cang SD
    Oncotarget; 2017 Jul; 8(30):49380-49394. PubMed ID: 28537902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination.
    Yu JS; Cui W
    Development; 2016 Sep; 143(17):3050-60. PubMed ID: 27578176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sanguinarine inhibits epithelial ovarian cancer development via regulating long non-coding RNA CASC2-EIF4A3 axis and/or inhibiting NF-κB signaling or PI3K/AKT/mTOR pathway.
    Zhang S; Leng T; Zhang Q; Zhao Q; Nie X; Yang L
    Biomed Pharmacother; 2018 Jun; 102():302-308. PubMed ID: 29571014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-99b suppresses human cervical cancer cell activity by inhibiting the PI3K/AKT/mTOR signaling pathway.
    Li YJ; Wang Y; Wang YY
    J Cell Physiol; 2019 Jun; 234(6):9577-9591. PubMed ID: 30480801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
    Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
    BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The PI3K/Akt/mTOR signaling pathway mediates insulin-like growth factor 1-induced E-cadherin down-regulation and cell proliferation in ovarian cancer cells.
    Lau MT; Leung PC
    Cancer Lett; 2012 Dec; 326(2):191-8. PubMed ID: 22922215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.